MedTrace Logo

Phase 1 Study of LQT-1213 in Healthy Adults

NCT05759962 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-09-26

No results posted yet for this study

Summary

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

Conditions

  • Long QT Syndrome

Interventions

DRUG

LQT-1213

LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

OTHER

Placebo

Matching Placebo

Sponsors & Collaborators

  • Thryv Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-14
Primary Completion
2023-03-05
Completion
2023-03-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05759962 on ClinicalTrials.gov